Risks and Benefits of Drugs Used in the Management and Prevention of Gout

Drug Safety

Volumn 11, Issue 4, 1994, Pages 252-258

  Conaghan, Philip G ^a   Day, Richard O ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOTROPIN; DICLOFENAC; FENOPROFEN; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PREDNISONE; PROBENECID; SULFINPYRAZONE; SULINDAC; URIC ACID;

BLOOD TOXICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY; HYPERURICEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FUNCTION; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RESPIRATORY FAILURE; REVIEW; RISK; URIC ACID BLOOD LEVEL;

ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; CORTICOTROPIN; DOUBLE-BLIND METHOD; GLUCOCORTICOIDS; GOUT; GOUT SUPPRESSANTS; HUMAN; PROBENECID; SULFINPYRAZONE;

EID: 0028108627     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199411040-00004     Document Type: Review

References (44)

1. Treatment of the gout and other forms of crystalinduced arthritis
2. Gout
3. Investigation and management of gout in the young and the elderly
4. What stops a gouty attack
5. Gout and hyperuricaemia
6. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario
7. Colchicine and gout
8. Systemic steroid therapy for acute gout: a clinical trial and review of the literature
9. Gout and hyperuricemia
10. NSAIDs: clinical efficacy and toxicity
11. Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs
12. Biochemical actions and clinical pharmacology of anti-inflammatory drugs
13. Nonsteroidal antiinflammatory drugs — differences and similarities
14. Nonsteroidal anti-inflammatory drugs. Differential use in older patients
15. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance
16. Does colchicine work? Results of the first controlled study in gout
17. Intravenous colchicine in the management of gouty arthritis
18. Colchicine, crystals, and neutrophil tyrosine phosphorylation
19. Analgesic-antipyretics and antiinflammatory agents: drugs used in the treatment of rheumatoid arthritis and gout
20. Measurement of colchicine in urine and peripheral leukocytes [abstract]
21. Colchicine intoxication: clinical pharmacology, risk factors, features, and management
22. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout
23. Review: systemic toxicity associated with the intravenous administration of colchicine — guidelines for use
24. Comparison of parenteral adrenocorticotrophic hormone with oral indomethacin in the treatment of acute gout
25. Local corticosteroid injection treatment in rheumatic disorders
26. Systemic corticosteroids in rheumatology
27. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study
28. The efficacy of colchicine prophylaxis in articular gout — a reappraisal after 20 years
29. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs
30. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency
31. Use and abuse of allopurinol
32. Single daily dose of allopurinol
33. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose
34. Intermittent control of hyperuricemia in the treatment of gout
35. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy
36. Allopurinol kinetics after massive overdosage
37. Acute adverse reactions attributed to allopurinol in hospitalised patients
38. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality
39. Allopurinol hepatotoxicity. Case report and literature review
40. Desensitization to allopurinol in patients with gout and cutaneous reactions
41. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization
42. Clinical pharmacokinetics of allopurinol
43. Inhibitors of tubular transport of organic compounds
44. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction